Evaluation of modified vaccinia virus Ankara expressing VP2 protein of infectious bursal disease virus as an immunogen in chickens.
10.4142/jvs.2012.13.2.199
- Author:
Flavia Adriana ZANETTI
1
;
Maria Paula Del Medico ZAJAC
;
Oscar Alberto TABOGA
;
Gabriela CALAMANTE
Author Information
1. Consejo Nacional de Investigaciones Cientificas y Tecnicas, Rivadavia 1917 (C1033AAJ) Ciudad Autonoma de Buenos Aires, Argentina. fzanetti@cnia.inta.gov.ar
- Publication Type:Brief Communication ; Controlled Clinical Trial ; Research Support, Non-U.S. Gov't
- Keywords:
chicken immunity;
IBDV;
MVA;
VP2 protein
- MeSH:
Animals;
Antibodies, Viral;
Birnaviridae Infections/prevention & control/*veterinary;
Cells, Cultured;
Chick Embryo;
Chickens;
Fibroblasts/metabolism;
Infectious bursal disease virus/*immunology;
Poultry Diseases/*prevention & control/virology;
Specific Pathogen-Free Organisms;
Vaccinia virus/*genetics/immunology/metabolism;
Viral Structural Proteins/genetics/*immunology/metabolism;
Viral Vaccines/*immunology
- From:Journal of Veterinary Science
2012;13(2):199-201
- CountryRepublic of Korea
- Language:English
-
Abstract:
A recombinant modified vaccinia Ankara (MVA) virus expressing mature viral protein 2 (VP2) of the infectious bursal disease virus (IBDV) was constructed to develop MVA-based vaccines for poultry. We demonstrated that this recombinant virus was able to induce a specific immune response by observing the production of anti-IBDV-seroneutralizing antibodies in specific pathogen-free chickens. Besides, as the epitopes of VP2 responsible to induce IBDV-neutralizing antibodies are discontinuous, our results suggest that VP2 protein expressed from MVA-VP2 maintained the correct conformational structure. To our knowledge, this is the first report on the usefulness of MVA-based vectors for developing recombinant vaccines for poultry.
